I bought in end last year on news of collaboration with Chinese re: dementure. A massive problem in China, as elsewhere. Paid 42p and within a few days was well over a pound. Top sliced 50% to get investment back plus some. Happy to hold the freeby shares, but it's going to be a looong wait. I'm sure it is doing all it can on research but will need a breakthrough on drugs, and if approved, no limit to how far sp can go. In MHO
My opinion is to avoid if you hold no shares in IXI and if you can sell without too big a loss do so and invest elsewhere. See testpack3 and my comments below...don't be fooled by large short term rises, the company do not have an income stream and need funding to do "something". When doing your research look at Phytopharm history too...they became Ixico.
A few thousand sells and the Mms would drop this share , and all week there have been mostly buys and the share price doesn't move at all...so what is going on...mm's playing silly games? This should be at the 80p level by now and heading to multiply many times over....just like GW pharma, and skyepharma...What does it to take to get the sp higher...a midas tip, perhaps? Strong buy
66%...very good point! This share was Phytopharm (PYM) and is following a similar pattern...share price goes up, investors pay high price, then down it drops. My PYM, now IXI, shares have lost 94% in 3 yrs and never been above what I paid for them. IXI shares will do the same unless they really develop a product of value otherwise you're just funding the directors...there are far better safer investments on FTSE100!! Just be wary, DYOR and good luck if you believe IXI is worth the investment.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.